13.10.2019
AAKASHAYA PATRA EXCLUSIVE STOCK FOR INVESTMENT:
GRANULES INDIA LTD
(CMP 100)
ENTER LEVEL – 95 TO 100 STOPLOSS 85 TARGET 130-150
IN 12 MONTHS
Granules
India Limited is a largescale vertically integrated Company founded in 1991
manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical
Formulation Intermediate (PFI) and Finished Dosage (FD). With a strong presence
across all three vertical, the Company has created a leadership position in the
off-patent drugs segment along with ensuring a strong presence in 'first line
of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
The Company,in line with its vision "to be the global leader in
pharmaceutical manufacturing by process innovation and unparalleled
efficiencies" has a global presence across 60+ countries servicing over
250 customers. With exports comprising over 80 percent of total revenue,
Granules is today the preferred supplier for some of the world's leading pharma
branded and generics companies.Dedicated to excellence in manufacturing,
quality and customer service, it possesses one of largest PFI and single site
FD facilities in the world. It is also home to one of the World's largest Paracetamol
API facilities. Company is having 4 operational plants located in Hyderabad (Jeedimetla,
Bonthapally and Gagillapur) and 1 in Vizag Pharma City.
It
has an equity base of just Rs.25.42crore that is supported by reserve of around
Rs.1504.05.Promoters hold 42.90%, FIIs hold 13.88%, Other DIIs hold 3.11% while
investing public hold 40.11% stake in the company.Company had posted excellent
numbers for FY19. Its PAT zoomed 78.30% Rs.236.41crore as against
Rs.132.59crore in FY18 on 34.72% higher sales of Rs.2279.20crore fetching an
EPS of Rs.9.30. It had reported strong numbers for Q1FY20 also. Its PAT zoomed
60.71% to Rs.83.24crore against Rs.51.80crore on 31.34% higher sales of
Rs.595.27crore fetching an EPS of Rs.3.27.Currently, the stock trades at a P/E
of just 9.8x. It has paid 50% interim dividend for FY19 and paid 25% final
dividend for FY19. It declares 25% interim dividend for FY20. "We continue
our growth momentum with the first quarter of FY20 showing encouraging
results.Our total Revenue from operations increased by 31% and net profit by
61% compared to the same period of previous year. The sustained growth in our
high volume based molecules business and our unwavering focus on U5 market
enabled us to achieve the growth. One of the key pillars of our business model
has been driving operational efficiencies and along with it a better product
mix helped us improve the Operating and Net profit margins in this quarter.
During the quarter we have filed 3 ANDAs and received approval for 2 ANDAs from
US FDA filed earlier. In continuation to our commitment to improve the leverage
position of the Company, this quarter has also witnessed improvement in our net
debt position." said Mr. Krishna Prasad Chigurupati, Chairman &
Managing Director of Granules India Limited.
Comments
Post a Comment